This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Tonix Pharmaceuticals Appoints Ronald R. Notvest, Ph.D. As Senior Vice President Of Commercial Planning And Development

NEW YORK, June 26, 2014 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a clinical-stage pharmaceutical company focused on common disorders of the central nervous system, has appointed Ronald R. Notvest, Ph.D. to its newly created position of Senior Vice President, Commercial Planning and Development.

Dr. Notvest joins Tonix from Evidec, where he applied his expertise in the commercial assessment and analysis of drug products on behalf of a variety of biopharmaceutical industry clients since founding the firm in 2002. From 1992 to 2002, Dr. Notvest held several commercial management positions at Wyeth-Ayerst Pharmaceuticals, including Senior Product Manager of Specialty Products Marketing, where he launched and marketed Rapamune® as well as prepared for the launch of Verdia®. As Associate Director for New Products Marketing, he was responsible for the commercial strategy of a portfolio of pharmaceutical products targeting central nervous system, asthma, immunology, cardiovascular, metabolic and endocrine disorders. Prior to 1992, Dr. Notvest held various scientific and management positions at Wyeth-Ayerst Research, including Section Head with responsibility for managing the drug discovery program for excitatory amino acids. Dr. Notvest earned a B.A. in biology from the University of Delaware as well as a Ph.D. in physiology and an M.B.A. in finance from Rutgers University.

Dr. Notvest said, "As the pharmaceutical reimbursement landscape continues to evolve, I believe it essential to conduct market research, analysis and planning in tandem with drug development. I look forward to working with the Tonix team to develop commercial strategies for its candidates with the goal of optimizing their value."

Seth Lederman, M.D., Chairman and Chief Executive Officer of Tonix, commented, "With a background that combines elements of science and business within the pharmaceutical context, Ron brings a unique set of analytical skills and marketing insights to our company, and we are pleased to have him join Tonix to direct our commercial planning and development activities. Whether we commercialize our prospective products directly or through partners, we expect that Ron's strategic perspective will better position our pharmaceutical assets to broadly address undertreated disorders."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,098.59 +86.65 0.48%
S&P 500 2,114.12 +4.52 0.21%
NASDAQ 5,092.5770 +16.0530 0.32%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs